Transient eruptive keratoacanthomas associated with nivolumab-Reference-Cited by-同舟云学术

Transient eruptive keratoacanthomas associated with nivolumab

Published:2019-04 Issue:4 Volume:5 Page:342-345
ISSN:2352-5126
Container-title:JAAD Case Reports
language:en
Short-container-title:JAAD Case Reports

Author:

Antonov Nina K.,Nair Kesav G.,Halasz Charles L.

Publisher

Elsevier BV

Subject

Dermatology

Reference8 articles.

1. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort;Hwang;J Am Acad Dermatol,2016

2. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors;Lopez;Int J Dermatol,2018

3. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy;Curry;J Cutan Pathol,2017

4. Eruptive keratoacanthomas associated with pembrolizumab therapy;Freites-Martinez;JAMA Dermatol,2017

5. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab;Fujimura;J Dermatol,2018

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Squamous Cell Carcinoma and its Precursors;Rook's Textbook of Dermatology;2024-03-19

2. Cemiplimab-Associated Eruption of Generalized Eruptive Keratoacanthoma of Grzybowski;Cutis;2024-01-01

3. Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF-β and PD-L1;Frontiers in Oncology;2023-08-01

4. Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma;Cutis;2023-05

5. A Case of Transient Eruptive Keratoacanthoma Associated With Nivolumab;Journal of the Dermatology Nurses' Association;2023-03